HOPO Therapeutics
HOPO Therapeutics
Home
About
Company
People
Careers
FAQ
Our Focus Areas
Radiological Hazards
Lead Poisoning
Gadolinium Toxicity
Our Science
Discovery & Development
HOPO 14-1
Publications
News
Contact
Rebecca J Abergel
Latest
238 Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice
Solution Thermodynamic Stability of Complexes Formed with the Octadentate Hydroxypyridinonate Ligand 3,4,3-LI(1,2-HOPO): A Critical Feature for Efficient Chelation of Lanthanide(IV) and Actinide(IV) Ions
Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.
3,4,3-LI(1,2-HOPO): In vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation
Cite
×